Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
EDSA Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 12, 2026
Report Source: 2026 2nd Quarter Report
Edesa Biotech Inc. Stock Analysis EDSA
United States Health Care Micro Cap Report: Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquisition, development, and commercialization of drug candidates for medical dermatology and respiratory diseases. The company is headquartered in Markham, Ontario and currently employs 17 full-time employees. The company went IPO on 2008-08-25. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Read More Edesa Biotech Inc (EDSA) Chart
Key Statistics of Edesa Biotech Inc (EDSA)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$6.69Volume
123.28KP/E Ratio (TTM)
-52 Week Range
Market Cap
96.66MAvg. Volume
274.23KDividend Yield
-Financial Metrics & Statements of Edesa Biotech Inc (EDSA)
FAQ's for Edesa Biotech Inc (EDSA)
- According to Musaffa’s Shariah screening methodology, Edesa Biotech Inc (EDSA) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Edesa Biotech Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Edesa Biotech Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Edesa Biotech Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Edesa Biotech Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Edesa Biotech Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.